ERIS vs THEMISMED: Stock Comparison

ERIS LIFESCIENCES vs THEMIS MEDICAREUpdated 11 Sept 26, 4:08 PM ISTNSE & company filings

ERIS LIFESCIENCES is the larger company by market capitalisation. ERIS LIFESCIENCES shows a lower P/E, a higher ROE and a higher dividend yield, while THEMIS MEDICARE shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

ERIS leads 11; THEMISMED leads 2 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

ERISTHEMISMED

Valuation lens

What price are you paying?

Market CapContext only
₹18,777 Cr
₹1,187 Cr
P/E RatioERIS has the lower reading
28.98x
30.51x
P/B RatioTHEMISMED has the lower reading
4.81x
3.06x
EPSERIS has the higher reading
₹10.28
₹3.12
Book ValueContext only
₹281.12
₹43.28
Dividend YieldERIS has the higher reading
0.53%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
ERIS is the larger company
₹18,777 Cr vs ₹1,187 Cr
P/E Ratio
ERIS has a lower P/E
28.98x vs 30.51x
P/B Ratio
THEMISMED has a lower P/B
3.06x vs 4.81x
EPS
ERIS has higher earnings per share
₹10.28 vs ₹3.12
Dividend Yield
ERIS has a higher dividend yield
0.53% vs 0%
Revenue Growth (TTM YoY)
ERIS has faster revenue growth
7.1% vs 6.7%
EPS Growth (TTM YoY)
ERIS has faster EPS growth
200% vs 0%
Qtr Sales Growth
ERIS has stronger quarterly sales growth
96.68% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricERISTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricERISTHEMISMED
Live Price₹1,355.5₹128.25
Day Change-0.08%-2.89%
Volume24,9681.11 L
52-Week High₹1,740₹148
52-Week Low₹1,200₹64.95
Distance from 52W High-22.1%-13.34%

Valuation

MetricERISTHEMISMED
Market Cap₹18,777 Cr₹1,187 Cr
P/E Ratio28.98x30.51x
P/B Ratio4.81x3.06x
EPS₹10.28₹3.12
Book Value₹281.12₹43.28
Dividend Yield0.53%0%

Growth

MetricERISTHEMISMED
Revenue Growth (TTM YoY)7.1%6.7%
EPS Growth (TTM YoY)200%0%
Qtr Sales Growth96.68%0%
Qtr Profit Growth196.73%16.76%

Profitability & Leverage

MetricERISTHEMISMED
ROE7.64%-4.71%
ROCE6.96%-0.63%
Net Margin19.89%0.33%
Operating Margin29.73%-0.79%
Debt to Equity0.65x0.33x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricERISTHEMISMED
Promoter Holding54.14% 0.22 pp57.5%
FII Holding5.75% 0.64 pp0.01% 0.1 pp
DII Holding20.72% 0.37 pp0.01%
Public Holding19.4% 0.07 pp32.87% 0.09 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ERIS LIFESCIENCES and THEMIS MEDICARE.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.